Fig. 5.

Developmental timelines for EGFR tyrosine kinase inhibitors (A) and cilengitide (B). Clinical studies outlined in black were conducted with newly diagnosed GBM patients, unless otherwise noted. Preclinical studies are highlighted in gray and were performed with established GBM xenograft models, unless otherwise noted.